With a flurry of high capital collaborations and partnership deals from the likes of C4T, Merck KgGA, Monte Rosa, Proxygen, Orum, and momentum building in clinic with BTK degraders, ER degraders and many more assets. It has never been more import to re-join forces at the 7th TPD & Induced Proximity Summit, the longest standing and most comprehensive protein degradation and proximity based conference.

Spanning foundational research and discovery, through to IND-filing and clinical trials, this is the world’s definitive meeting to discuss opportunities and challenges the TPD & Induced Proximity field must address to expand the target space and facilitate the discovery and development of therapeutically relevant degraders, blockers, stabilizers and inducers of protein-protein interactions. Whether you’re entering the space for the first time or a well-seasoned TPD veteran, this forum will equip you with the knowhow and connections to make rapid advances in your work.

The 85+ industry expert speakers include:

• Alessio Ciulli, Founder & Director, Centre for Targeted Protein Degradation (University of Dundee)
• Stuart Schreiber, Founding Chief Executive Officer, Arena Bioworks
• Sharon Townson, Chief Scientific Officer, Monte Rosa Therapeutics
• Nello Mainolfi, Founder, President & Chief Executive Officer, Kymera Therapeutics
• Adrian Gottschalk, Chief Executive Officer, Foghorn Therapeutics
• Andrew Hirsch, Chief Executive Officer, C4 Therapeutics
• Arthur T. Sands, Chief Executive Officer, Nurix Therapeutics
• Chinatsu Sakata-Sakur, Vice President, Astellas Pharma

Assembling over 500 TPD & Induced Proximity enthusiasts from across every corner of the landscape, we have left no stone unturned to deliver the full breadth and depth of protein degradation and modulation research with SureTACs, EpiTACs, RIPTACs, Molecular Gates, and so much more.

View the agenda here: https://ter.li/8nvx3c